Restore Medical, a clinical-stage medtech startup based in Israel, developing transcatheter therapies for heart failure, has announced the successful closing of a $23 million Series B financing round.
The round is co-led by Pitango HealthTech and a global strategic healthcare partner, alongside the European Innovation Council (EIC) Fund, and continued support from existing investors including Peregrine Ventures, which has supported the company since its inception, and another strategic partner.
The round will fund the completion of Restore Medical's ongoing European feasibility study, which has demonstrated promising long-term safety and efficacy data, including meaningful improvements in ventricular reverse remodeling, hemodynamic performance, and patient functional capacity.
The investment will also support the launch of a US-based clinical study, following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) in 2024.
Restore Medical's unique transcatheter approach introduces a new minimally invasive therapeutic option for heart failure patients who have limited effective treatments today.
Heart failure is a chronic, progressive condition in which the heart is unable to pump blood effectively to meet the body's needs. It remains one of the leading causes of hospitalization and mortality worldwide, particularly in patients with Heart Failure with reduced Ejection Fraction (HFrEF). Despite advancements in pharmacological treatments, a significant portion of patients remain symptomatic and at high risk of repeated hospitalizations, impaired quality of life, and premature death. The need for innovative, device-based therapies is growing rapidly as existing medical options reach their limits in addressing advanced heart failure.
